Viking Global Investors
Viking Global Investors is a long/short equity hedge fund. The fund employs a bottom-up fundamental stock-picking strategy for its investments in equities in the U.S. and Europe. It focuses on the financial, telecommunication, media, technology, and consumer sectors. Viking Global Investors is based in New York and was founded in October, 1999 by Andreas Halvorsen, David Ott, and Brian Olson.
Messers. Halvorsen, Ott, and Olson worked together at Tiger Management Corp. All three left Tiger in early 1999.
View Older Stories View More Recent Stories
-
Valsoft Corporation Secures $150M to Further Accelerate Growth in Vertical Market Software Sector
-
GondolaBio and n-Lorem Foundation Partner to Advance Novel ASO Therapies for Genetic Diseases
-
Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-Resistant Epilepsy Announced at 2024 Annual Meeting of the American Epilepsy Society
-
ID.me Announces Closing of Secondary Tender
-
Form SC 13G/A Tourmaline Bio, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Ginkgo Bioworks Holdings Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Roivant Sciences Ltd. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A PepGen Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Edgewise Therapeutics, Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A 4D Molecular Therapeutic Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Viking Therapeutics, Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Verastem, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form 13F-HR VIKING GLOBAL INVESTORS For: Sep 30
-
Tesla, financials and other 'Trump trades' drew funds in Q3, filings show
-
Metsera Secures $215 Million Series B Financing to Further Accelerate Portfolio
-
Form SC 13D/A Cazoo Group Ltd Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13D/A BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Ayana Bio to Showcase Plant Cell Advantage™ Health & Wellness Ingredients at SupplySide West 2024
-
Form D/A Viking Global Opportunit
-
Form D/A Viking Global Opportunit
-
Form D/A Viking Global Equities
-
Form D/A Viking Global Equities
-
Form D/A Viking Global Equities
-
Triveni Bio Raises $115 Million Series B Financing to Expand Pipeline of Therapeutics Addressing Immunological and Inflammatory (I&I) Disorders
-
Form SC 13G BIOMARIN PHARMACEUTICAL Filed by: VIKING GLOBAL INVESTORS LP
-
Neurona Therapeutics Announces Participation in Upcoming Investor Conferences in October
-
Humaneva Group Secures Major US Private Equity Investment to Accelerate Global Clinical Research Market Expansion
-
Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate
-
Ted Seides of Capital Allocators Releases Private Equity Deals
-
Ted Seides of Capital Allocators Releases Private Equity Deals
-
Form N-PX VIKING GLOBAL INVESTORS For: Jun 30
-
Synapticure and Pearl Health Partner to Provide Specialized Neurologists and Personalized Patient and Caregiver Support to Medicare Patients with Dementia
-
Form SC 13D/A BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form 13F-HR VIKING GLOBAL INVESTORS For: Jun 30
-
Pearl Health Partners With PraxisCare and Adaugeo Healthcare Solutions to Expand Value-Based Care Network in the Pacific Northwest
-
Ayana Bio Welcomes Biotechnology Veteran Jill Zullo to its Board of Directors
-
Pearl Health and MDX Hawaii Partner to Expand Access to Value-Based Care
-
Magenta Medical Closes $105M Financing Led by Novo Holdings
-
Antheia Announces New Funding to Support Domestic Production of Critical Pharmaceutical Ingredients
-
Form SC 13G Longboard Pharmaceutical Filed by: VIKING GLOBAL INVESTORS LP
-
AlphaSense Completes Acquisition Of Tegus
-
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
-
Pearl Health CEO Michael Kopko recognized as an EY Entrepreneur Of The Year® 2024 New York Award Winner
-
Form SC 13G/A APi Group Corp Filed by: VIKING GLOBAL INVESTORS LP
-
Neurona Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for NRTX-1001 in Focal Epilepsy
-
Mexican Fintech Unicorn Clip Announces US$100 Million Investment
-
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
-
AlphaSense valued at $4 billion in latest funding, agrees $930 million deal for rival Tegus
-
AlphaSense to Join Forces with Tegus; Increases Latest Valuation to $4B
-
Form SC 13G Inhibrx Biosciences, Filed by: VIKING GLOBAL INVESTORS LP
